Biotechnology

Genprex

Genprex released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -26.4522

Genprex released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.9957 (forecast USD -32)

Genprex Receives Patent Grant Notice for Reqorsa Gene Therapy Combined with PD-1 Antibodies for Cancer Treatment

Genprex Inc to present positive preclinical data of Reqorsa® gene therapy at cancer treatment conference

Genprex released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -8.4708 (forecast USD -35.5)

Genprex released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -20.1258

Genprex Leads in Progress on Alpha Cell Study

Genprex Announces Positive Preclinical Results for Diabetes Candidate Drug GPX-002

Genprex Inc. Restores Compliance with NASDAQ Requirements

Genprex released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -12.9857 (forecast USD -41)

Genprex Obtains Exclusive Patent License for Reqorsa® Gene Therapy

Genprex Unveils Promising Preclinical Data for Gene Therapy REQORSA at AACR

Genprex Announces Positive Preclinical Results for Diabetes Gene Therapy

Genprex Signs Exclusive Licensing Agreement for Reqorsa Gene Therapy with NYU Langone Health

Genprex's Reqorsa® Gene Therapy Shows Promising Preclinical Results for Lung Cancer Treatment

Genprex released FY2024 Q4 earnings on April 1, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -26.39 (forecast USD -41)

Genprex released FY2024 earnings on April 1, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -266.953 (forecast USD -285)

Genprex Inc Reports Quarterly Loss of $1.15 per Share, Analysts Rate 'Buy'

Genprex Inc Expected to Report EPS Loss of 39 Cents, Analyst Gives Buy Rating

Genprex, Inc. Announces Positive Preclinical Data for Immunogene Therapy Targeting Non-Small Cell Lung Cancer

A SPAC III Acquisition

PicoCELA

ECD Automotive Design

Davis Commodities

Paranovus ENT Tech

Starfighters Space

Universe Pharmaceuticals

Sidus Space

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Titan Mining

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap